Login
$ACET
$2.75 -$0.03 (1.08%) Live

$ACET SEC Filings

Filed On Filing
13 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation

On November 11, 2026, Andrew Sinclair, Ph.D., a Class III member of the board of directors (the “Board”) of Adicet Bio, Inc. (the “Company”), notified the Company of his resignation from the Board, the Audit Committee of the Board (the “...

05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

Phase 1 data for prulacabtagene leucel (prula-cel, formerly ADI-001) demonstrated durable responses and a favorable safety profile in patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (LN)

28 Oct 2026 SCHEDULE 13G/A
23 Oct 2026 SCHEDULE 13G
28 Sep 2026 8-K: Regulation FD Disclosure; Other Events

Forward-Looking Statements This presentation contains “forward-looking statements” of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words “anticip...

08 Sep 2026 8-K: Regulation FD Disclosure

Forward-Looking Statements This presentation contains “forward-looking statements” of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words “anticip...

01 Sep 2026 8-K: Regulation FD Disclosure

Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update

14 Aug 2026 SCHEDULE 13G/A
07 Aug 2026 Form 4: Klickstein Lloyd, Director

Granted 18,300 Stock Option (Right to Buy)

05 Aug 2026 10-Q
05 Aug 2026 8-K: Results of Operations and Financial Condition

Company to provide a comprehensive Phase 1 clinical update for prulacabtagene leucel (prula-cel, formerly ADI-001), featuring data from 22 patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) with a minimum of 6 mont...

23 Jun 2026 Form 4: Schor Chen, Director

Granted 55,000 Stock Option (Right to Buy)

23 Jun 2026 Form 4: Aftab Blake, Chief Scientific Officer

Granted 55,000 Stock Option (Right to Buy)

23 Jun 2026 Form 4: Dubin Steve, Director

Granted 4,200 Stock Option (Right to Buy)

23 Jun 2026 Form 4: Chodakewitz Jeffrey, Director

Granted 4,200 Stock Option (Right to Buy)

23 Jun 2026 Form 4: Grissinger Michael, Director

Granted 4,200 Stock Option (Right to Buy)

23 Jun 2026 Form 4: Sinclair Andrew, Director

Granted 4,200 Stock Option (Right to Buy)

23 Jun 2026 Form 4: Peng Katie, Director

Granted 4,200 Stock Option (Right to Buy)

23 Jun 2026 Form 4: Klickstein Lloyd, Director

Granted 4,200 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support